Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Checked against the public recordLast updated Feb 8, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- OSI Pharmaceuticals
- Interventions being studied
- Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological). * Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer. * Measurable disease per RECIST criteria. * Adequate bone marrow, hepatic and renal function. Exclusion Criteria: * Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years. * Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days. * Known hypersensitivity to minocycline. * History of serious cardiac disease that is not controlled. * Serious eye conditions. * Prior treatment with inhibitors of EGFR of any kind.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Institute for Drug Development Cancer Therapy and Research CenterSan Antonio, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 8, 2018. Always confirm current availability with the study team.